Skinvisible, Inc. (SKVI) Receives European Patent Notice for Invisicare  
9/23/2011 10:34:39 AM

LAS VEGAS, Sept. 22, 2011 (GLOBE NEWSWIRE) -- Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI) (OTCBB:SKVI) announced today that the European Patent Office (EPO) has issued a Notice of Intent to Grant European patent application number 02752847.0 pertaining to Skinvisible's drug delivery system, Invisicare, which is a drug delivery technology used in prescription, over-the-counter and cosmeceutical products. The comprehensive patent protects Invisicare in three main areas: its composition, its method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is used for. This patent provides protection with claims that were also patented in the other Invisicare international patents.